Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 4/20 | 0.45 |
| ▸ | RAB9A | P51151 | 4/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | TP53 | P04637 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | TSHR | P16473 | 2/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | DGAT1 | O75907 | 2/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.41 |
| ▸ | CDK5R1 | Q15078 | 2/20 | 0.41 |
| ▸ | RET | P07949 | 1/20 | 0.40 |
| ▸ | MGLL | Q99685 | 4/20 | 0.40 |
| ▸ | EGFR | P00533 | 1/20 | 0.39 |
| ▸ | KDR | P35968 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21462384 | 0.81 | NPC1 (0.42) | NPC1RAB9ASMN1; SMN2MEN1KMT2A | |
| SCHEMBL21462334 | 0.81 | NPC1 (0.52) | NPC1RAB9ASMN1; SMN2MEN1KMT2A | |
| SCHEMBL23327775 | 0.80 | NPC1 (0.42) | NPC1RAB9ASMN1; SMN2MEN1KMT2A | |
| SCHEMBL21462440 | 0.80 | PDE10A (0.49) | NPC1RAB9ASMN1; SMN2MEN1KMT2A | |
| SCHEMBL23327790 | 0.79 | NPC1 (0.50) | NPC1RAB9ASMN1; SMN2MEN1KMT2A | |
| SCHEMBL21462350 | 0.78 | NPC1 (0.47) | NPC1RAB9ASMN1; SMN2MEN1KMT2A | |
| SCHEMBL23327544 | 0.78 | NPC1 (0.47) | NPC1RAB9ASMN1; SMN2MEN1KMT2A | |
| SCHEMBL19341609 | 0.75 | RAB9A (0.51) | NPC1RAB9ASMN1; SMN2MEN1KMT2A | |
| SCHEMBL2055243 | 0.74 | CDK5 (0.61) | NPC1RAB9ASMN1; SMN2MEN1KMT2A | |
| SCHEMBL21462716 | 0.73 | NPC1 (0.42) | NPC1RAB9ASMN1; SMN2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210138092-A1 | SELECTIVE LIGANDS FOR TAU AGGREGATES | CBD SOLUTIONS AB (SE) | 2021-05-13 | — | — | US | claimed |
| US-12636385-B2 | Selective ligands for tau aggregates | SENTONIX, INC. (US) | 2026-05-26 | — | — | US | disclosed |
| US-20210138092-A1 | SELECTIVE LIGANDS FOR TAU AGGREGATES | CBD SOLUTIONS AB (SE) | 2021-05-13 | — | — | US | disclosed |
| US-20210138092-A1 | SELECTIVE LIGANDS FOR TAU AGGREGATES | CBD SOLUTIONS AB (SE) | 2021-05-13 | — | — | US | disclosed |
| EP-3774771-A1 | SELECTIVE LIGANDS FOR TAU AGGREGATES | Karin&Sten Mortstedt CBD Solutions AB (SE) | 2021-02-17 | — | — | EP | disclosed |
| WO-2019197502-A1 | SELECTIVE LIGANDS FOR TAU AGGREGATES | KARIN & STEN MORTSTEDT CBD SOLUTIONS AB (SE) | 2019-10-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210138092-A1 | SELECTIVE LIGANDS FOR TAU AGGREGATES | MAPT, PSEN1, PSEN2 | NPC1 558/4885RAB9A 1319/4885SMN1; SMN2 144/4885 |
| US-12636385-B2 | Selective ligands for tau aggregates | MAPT, PSEN2, PSEN1 | NPC1 242/4885RAB9A 1472/4885SMN1; SMN2 45/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.